Dr Gerds on Unmet Needs in Low-Risk Myelofibrosis

Unmet needs in myelofibrosis and future outlooksПодробнее

Addressing unmet needs in myelofibrosis: alleviating anemiaПодробнее

Dr. Gerds on Addressing Anemia in MyelofibrosisПодробнее

Myelofibrosis: Research to Practice- Are We Making a Difference?- Dr. Michael Savona, 10/2/13Подробнее

Management of Low-Risk Primary MyelofibrosisПодробнее

Dr. Garcia on Unmet Need in MyelofibrosisПодробнее

Unmet needs in myelofibrosisПодробнее

Dr. Kremyanskaya on Unmet Needs in MyelofibrosisПодробнее

Unmet Needs in MyelofibrosisПодробнее

Ruxolitinib in the real world: myelofibrosisПодробнее

Dr. Gerds on Luspatercept to Treat Anemia in MyelofibrosisПодробнее

Dr. Gerds on Design and Safety Analysis of a Trial With Luspatercept in MyelofibrosisПодробнее

Myelofibrosis ‐ Dr Gabriela HobbsПодробнее

Treating Intermediate/High-Risk Primary MyelofibrosisПодробнее

Update on JAK Inhibitors for Myelofibrosis: There is more than oneПодробнее

Dr. Gerds on Future Treatment of Patients With Myeloproliferative NeoplasmsПодробнее

Myelofibrosis: unmet needsПодробнее

Debate: Survival benefit of JAK2 inhibitors in MyelofibrosisПодробнее

Phase II trial of luspatercept in myelofibrosis-associated anemiaПодробнее